Earnings Reports

Found 78,802 articles

• Danaher Schedules Third Quarter 2021 Earnings Conference Call

  9/21/2021

  Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

• 

  Marinus on Track to Capitalize on Recent Seizure Drug Approval

  5/13/2022

  Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.

• SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

  5/13/2022

  SeqLL Inc. announced its operating and financial results for the first quarter ended March 31, 2021, and provided a corporate update.

• Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

  5/13/2022

  Tempest Therapeutics, Inc. reported financial results for the quarter ended March 31, 2022 and provided a corporate update.

• Spectral Announces First Quarter 2022 Results and Provides Corporate Update

  5/13/2022

  Spectral Medical Inc. announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update

  5/13/2022

  Kintara Therapeutics, Inc. today announced financial results for its fiscal third quarter ended March 31, 2022 and provided a corporate update.

• Iterum Therapeutics Reports First Quarter 2022 Financial Results

  5/13/2022

  Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2022.

• ProMIS Neurosciences Announces First Quarter 2022 Results

  5/13/2022

  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021.

• Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/13/2022

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Humacyte First Quarter 2022 Financial Results and Business Update

  5/13/2022

  Humacyte, Inc. today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.

• Abeona Therapeutics Reports First Quarter 2022 Financial Results

  5/13/2022

  Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the first quarter of 2022.

• ReWalk Robotics Reports First Quarter 2022 Financial Results

  5/13/2022

  ReWalk Robotics Ltd. announced its financial results for the three months ended March 31, 2022.

• Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results

  5/13/2022

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2022.

• RaySearch releases preliminary resultat for the first quarter of 2022

  5/13/2022

  RaySearch Laboratories AB releases preliminary figures for the first quarter of 2022. Order intake increases by 88 percent to SEK 273 million, sales increase by 28 percent to SEK 208 million and EBIT amounts to SEK 29 million.

• Marker Therapeutics Reports Q1 2022 Operating and Financial Results

  5/13/2022

  Marker Therapeutics, Inc. today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

• Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update

  5/13/2022

  Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update.

• Seegene reports first quarter 2022 financial results

  5/13/2022

  Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, today reported first quarter revenue of KRW 451.5 billion and operating profit of KRW 199.7 billion.

• Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

  5/13/2022

  Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.

• Leap Therapeutics Reports First Quarter 2022 Financial Results

  5/13/2022

  Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2022.

• Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones

  5/13/2022

  Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate milestones.